{"disease":{"id":"chronic-lymphocytic-leukaemia-cll","name":"chronic lymphocytic leukaemia cll"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05645172","title":"Retention Rate of Acalabrutinib in a Non-interventional Setting","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":137,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06762431","title":"Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":60,"lead_sponsor_name":"Vitebsk Regional Clinical Cancer Centre","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}